IL6 and myocardial infarction: For these reasons, researchers moved to IL-6; they found that elevated levels of IL-6 are associated with increased risk of future myocardial infarction (MI) in healthy men (42) and treatment with tocilizumab (IL-6Ra) significantly attenuates inflammation and PCI-related troponin T release in patients with acute non-ST-elevation myocardial infarction (NSTEMI) (23).